Lexeo Therapeutics

Advancing novel therapies in cardiovascular genetic diseases.

Advancing Gene Therapy in Monogenic Diseases

Friedreich ataxia (FA) is a rare, hereditary disease caused by a mutation in the FXN gene, leading to mitochondrial dysfunction and multisystem complications, including cardiac issues.

ACM is a genetic heart disease primarily characterized by myocardial cell loss and the replacement of heart muscle with fibrotic tissue and fatty deposits.

Positron emission tomography (PET) images 24 hr after administration of I-124 labeled AAVrh10 by the intracisternal route to a nonhuman primate, showing differences between serotype naïve (left) and serotype immune status.

Late infantile Batten disease (CLN2 disease) is an autosomal recessive, neurodegenerative lysosomal storage disorder caused by mutations in the CLN2 gene.

Lexeo Therapeutics focuses on therapies for patients with genetic diseases, recruiting talent to support its work.

Lexeo's management team consists of pioneers and driven leaders with decades of development experience in gene therapy and rare diseases

Lexeo Therapeutics is a New York City-based fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic cardiovascular conditions and genetic conditions of the central nervous system (CNS).

Lexeo Therapeutics develops treatments targeting the underlying causes of genetic diseases.

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated.

The company evaluates investigational therapies in clinical trials to advance its mission of treating genetic diseases.